Genzyme's gambit: A hedge against Carl Icahn
18 February 2010
Christopher Spillane
Please Login to read the full article.
18 February 2010
Christopher Spillane
The fall in Genzyme's share price made it an obvious target. The Massachusetts based biotech company's value had been hammered by its inability to deal with several contamination issues in the manufacture of its rare genetic disease treatments.
Genzyme's failure to remedy the US...
Please Login to read the full article.
RELATED CONTENT
ANALYSIS
Other Informa Analysis
COMMENT
Other Informa Comment
FEATURES
Other Informa Features
EVENTS
09 February 2012
London
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
